Saltar para:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Início > Publicações > Visualização > Botulinum toxin treatment for bladder dysfunction

Publicações

Botulinum toxin treatment for bladder dysfunction

Título
Botulinum toxin treatment for bladder dysfunction
Tipo
Outra Publicação em Revista Científica Internacional
Ano
2013
Autores
Santos Silva, A
(Autor)
Outra
A pessoa não pertence à instituição. A pessoa não pertence à instituição. A pessoa não pertence à instituição. Sem AUTHENTICUS Sem ORCID
Francisco Cruz
(Autor)
FMUP
Revista
Vol. 20
Páginas: 956-962
ISSN: 0919-8172
Editora: Wiley-Blackwell
Outras Informações
ID Authenticus: P-006-6VP
Abstract (EN): Botulinum toxin A is available under three different protein complexes that are not interchangeable until appropriate comparative studies are undertaken. The best studied for the treatment of urinary incontinence as a result of neurogenic detrusor overactivity and overactive bladder/idiopathic detrusor overactivity is onabotulinum toxin A. This brand is only approved for the treatment of urinary incontinence as a result of neurogenic detrusor overactivity at a dose of 200U and idiopathic detrusor overactivity at a dose of 100U. In patients with detrusor overactivity as a result of spinal cord injury or multiple sclerosis, 200U of onabotulinum toxin A should be injected in 30 different sites above the trigone. It was shown to be highly effective in curing or decreasing urinary symptoms of incontinence, increasing quality of life, increasing bladder capacity and decreasing maximal detrusor pressure. This effect was independent of the concomitant use of oral anticholinergic drugs. Adverse events were mild, mainly urinary tract infections and high postvoid residual requiring clean intermittent catheterization. In patients with overactive bladder/idiopathic detrusor overactivity, 100U of onabotulinum toxin A should be injected in 20 sites above the trigone. It markedly decreases urinary incontinence and improves quality of life. Frequency and urgency episodes are also decreased. Adverse events are mild, mainly urinary tract infections and urinary retention. The latter occurred in just 5% of the patients. Candidates for onabotulinum toxin A treatment should be warned that the effect of the toxin is transient and that repeated injections will be required to maintain the effect in the long term. There is no evidence that repeated injections will have a decreased efficacy.
Idioma: Inglês
Tipo (Avaliação Docente): Científica
Nº de páginas: 7
Documentos
Não foi encontrado nenhum documento associado à publicação.
Publicações Relacionadas

Dos mesmos autores

Renal Cell Carcinoma with Venous Thrombus: Should Surgery Be Offered When Metastasis Is Present at Diagnosis? (2018)
Outra Publicação em Revista Científica Internacional
Manso, M; Pacheco Figueiredo, L; Santos Silva, A; João Silva; Carlos Silva; Francisco Cruz

Da mesma revista

Moment of inertia as a means to evaluate the biomechanical impact of pelvic organ prolapse (2013)
Artigo em Revista Científica Internacional
brandao, s; da roza, t; mascarenhas, t; duarte, s; ramos, i; parente, m; jorge, rn
Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study) (2016)
Artigo em Revista Científica Internacional
Montorsi, F; Gandaglia, G; Chapple, C; Francisco Cruz; Desgrandchamps, F; Llorente, C
Recomendar Página Voltar ao Topo
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Termos e Condições  I Acessibilidade  I Índice A-Z
Página gerada em: 2025-09-03 às 05:25:18 | Política de Privacidade | Política de Proteção de Dados Pessoais | Denúncias